390. Phylogenetic Analysis of HIV-1 Subtypes and Drug Resistance Profile Among Treatment-Nave People in Kuwait
Session: Poster Abstract Session: HIV Epidemiology: HIV Drug Resistance - Molecular Epi and Transmission
Thursday, October 8, 2015
Room: Poster Hall
Posters
  • IDSA HIV1.pdf (131.2 kB)
  • Background:

    Mutations associated with resistance to antiretroviral therapy are a major cause of failure to treatment, and surveillance for the emergence of HIV resistance became a component of all antiretroviral treatment programs. As transmission of resistant viruses to newly infected persons is possible, we aimed to determine the prevalence of primary mutations associated with antiretroviral resistance among treatment-nave patients, with respect to HIV subtype.

    Methods:

    Fourty three plasma samples were collected from treatment-nave HIV-infected patients, between June 2011 and October 2014.  

    Viral RNA was extracted from plasma samples of 43 treatment-nave patients. Protease (PR) and reverse transcriptase (RT) regions were amplified and sequenced using the TRUGENE HIV-1 Genotyping Assay. A phylogenetic analysis was performed for HIV subtype assignment. 

    Results:

    Complete sequence information could be obtained for 35 patients. A total of ten different HIV-1 subtypes and recombinant forms were found in Kuwait with predominance of subtypes B, C and CRF01_AE. A62V and A98G were non-polymorphic resistance-associated mutations (RAMs) detected in the RT region of two and three patients, respectively. Non-polymorphic mutations associated with resistance to protease inhibitors were not detected. 

    Conclusion:

    Our results support continuous surveillance of resistance-associated mutations in newly infected individuals to assess the effectiveness of first-line antiretroviral regimen available in Kuwait.

    Table. HIV-1 subtypes in ART-nave patients from Kuwait

    Subtype

    Total

    n (%)

    Female

    n (%)

    Male

    n (%)

    Kuwaiti

    n (%)

    Non-Kuwaiti

    n (%)

    A

    2 (5.7)

    0 (0)

    2 (7.4)

    1 (3.6)

    1 (14.3)

    B

    9 (25.7)

    1 (12.5)

    8 (29.6)

    7 (25.0)

    2 (28.6)

    C

    9 (25.7)

    3 (37.5)

    6 (22.2)

    6 (21.4)

    3 (42.9)

    CRF01_AE

    6 (17.1)

    3 (37.5)

    3 (11.1)

    6 (21.4)

    0 (0)

    CRF02_AG

    2 (5.7)

    0 (0)

    2 (7.4)

    2 (7.1)

    0 (0)

    CRF15_01B

    1 (2.9)

    0 (0)

    1 (3.7)

    1 (3.6)

    0 (0)

    CRF35_AD

    2 (5.7)

    0 (0)

    2 (7.4)

    1 (3.6)

    1 (14.3)

    CRF50_A1D

    1 (2.9)

    1 (12.5)

    0 (0)

    1 (3.6)

    0 (0)

    CRF53_01B

    2 (5.7)

    0 (0)

    2 (7.4)

    2 (7.1)

    0 (0)

    CRF55_01B

    1 (2.9)

    0 (0)

    1 (3.7)

    1 (3.6)

    0 (0)

    Total

    35

    8

    27

    28

    7

    Haya Altawalah, BSc. MBBS. FRCPath, Virology Unit, Ministry of health, Kuwait Cancer Control Center (KCCC), KUWAIT, Kuwait, Widad Al-Nakib, FRCPath, FIDSA, Microbiology Department, Kuwait University, Faculty Of Medicine, Kuwait, Kuwait and Wassim Chehadeh, PhD, Virology Unit, Faculty of Medicine, Kuwait, Kuwait

    Disclosures:

    H. Altawalah, None

    W. Al-Nakib, None

    W. Chehadeh, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.